Best Grants for Cancer Nonprofits in Iowa

Purpose

The purpose of this Request for Proposal (RFP) # COMPADM26001 is to solicit applications that will enable the Iowa Department of Health and Human Services (referred to as Agency) to select the most qualified applicant to provide Rural Iowa cancer service providers with expertise, assessment and evaluation, and technical assistance on evidence-based strategies for designing, implementing, and sustaining cancer-focused Hub and Spoke models for achieving success in the Combat Cancer Projects of Iowa's Rural Health Transformation Grant. Activities in the Combat Cancer initiative of the Healthy Hometowns project include the development of hub and spoke models for cancer care, including the development of rural provider strategic partnerships. This includes developing and implementing arrangements that include exchanging best practices and coordination of care (which includes but is not limited to remote care services), expanding access to specialty services in a financially sustainable manner, streamlining or centralizing functions to create cost savings, improving the financial viability of rural providers, preserving independence of rural providers, keeping care local in rural communities when possible and appropriate, and developing models of sustainability for rural cancer providers. Other efforts include the coordination of patient navigation and survivorship services and the oversight of fidelity to evidence-based cancer screening, treatment, and care coordination practices. The Contractor will also support long-term sustainability planning, including workforce development, tele-oncology integration, and alignment with Commission on Cancer (CoC) standards. This work implements a portion of the Combat Cancer: Prevent and Treat initiative of the Iowa Healthy Hometowns Project, funded through the Centers for Medicare & Medicaid Services’ Rural Health Transformation Program, opportunity #: CMS-RHT-26-001.

The Best and Brightest Rural Healthcare Workforce Recruitment Grant aims to enhance healthcare access in rural Iowa by recruiting qualified healthcare providers. This initiative, aligned with Iowa's Healthy Hometowns program, seeks to address workforce shortages and improve health outcomes through competitive incentives for providers. By fostering partnerships and investing in technology, the program focuses on creating sustainable care models that ensure quality healthcare delivery in underserved communities, ultimately aiming to elevate the standard of care in rural areas.

The Combat Cancer Health Hub Program Round 2, initiated by the Iowa Department of Health and Human Services, seeks qualified applicants to establish cancer Hub and Spoke sites aimed at improving access to treatment in rural Iowa. This program is part of the Healthy Hometowns Rural Health Transformation initiative, focusing on innovative healthcare delivery models to enhance cancer care, including chemotherapy and other treatments, diagnostics, and management services across rural communities.

The Schoen Family Charitable Trust Grant, established by John and Joan Schoen in 2005, is a 501(c)(3) organization dedicated to supporting Midwestern communities. With a board comprised of the founders' family members, the trust emphasizes charitable giving, allocating over 98% of funds to various causes. Their mission focuses on education, health, wellness, and family support, aiming to empower individuals and improve lives through targeted assistance and community engagement.

The Vince Lombardi Cancer Foundation (VLCF) has played a pivotal role in cancer research and education since its inception in 1971, raising over $21 million to support innovative treatments and compassionate care. This private foundation invites applications from recognized healthcare institutions, focusing on funding scientific and medical fellowships. VLCF is dedicated to preventing cancer and improving patient care, ensuring that the spirit of excellence continues in the fight against this disease.

The Pinetop Assistance League (PAL) Grant provides crucial financial support to elderly blues musicians, ensuring their well-being during emergencies. This grant, part of the Pinetop Perkins Foundation's mission, offers assistance for medical expenses, home care, and essential living costs. Eligible applicants must be professional artists aged 50 or older with a household income below $35,000. By addressing these needs, PAL plays a vital role in preserving the legacy and care of blues musicians.

The Patient-Centered Outcomes Research Institute (PCORI) is announcing funding for comparative clinical effectiveness research across the cancer care continuum. This initiative aims to empower researcher-community partnerships to tackle significant healthcare challenges faced by patients and caregivers in the U.S. The focus is on enhancing care delivery and outcomes by addressing barriers to screening, treatment, and follow-up care for cancer patients. Applications are encouraged to identify strategies that improve patient-centered outcomes.

The Cancer Center Improving Cancer Outcomes Pilot Funding, offered by the Indiana Clinical and Translational Sciences Institute (CTSI), aims to support innovative pilot projects that enhance cancer-related outcomes across the U.S. This program invites proposals focusing on populations with higher cancer burdens, emphasizing evidence-based strategies for prevention, detection, treatment, and survivorship. By fostering interdisciplinary collaboration, the initiative seeks to tackle real-world barriers and generate actionable solutions to improve community health.

This funding opportunity from the Patient-Centered Outcomes Research Institute aims to enhance health decision-making through comparative clinical effectiveness research, focusing on critical areas such as cancer, maternal health, and mental health. The initiative encourages robust observational studies that utilize existing data to derive patient-centered insights. Applications must address specific themes approved by PCORI and demonstrate potential benefits to the U.S. healthcare system, thus ensuring relevance and stakeholder engagement in research efforts.

The National Cancer Institute (NCI) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers for 2027-2029. This funding opportunity supports innovative translational research aimed at improving prevention, detection, and treatment of organ-specific cancers. Eligible projects may address related cancer types from the same organ system or focus on common biological mechanisms. The program emphasizes research that translates findings into clinical applications, with the goal of achieving a human endpoint during the grant period.

The Cancer Care Specialists of Illinois Scholarship offers financial assistance for tuition to high school seniors and healthcare professionals in oncology/hematology within Central and Southern Illinois. The scholarship supports educational pursuits and professional development in these fields. Applications are accepted monthly, with a deadline for 2025 set for December 1st. Eligible candidates must maintain a GPA of 3.0 and reside in specific counties, ensuring support for local talent in healthcare.

The ASTRO-ACS Clinician Scientist Development Award aims to support full-time faculty members in radiation oncology who aspire to become independent investigators. Co-funded by the American Cancer Society and the American Society for Radiation Oncology, this grant provides $135,000 per year for 3 to 5 years, along with 8% allowable indirect costs. It encourages applications from underrepresented groups and those with disabilities, fostering diversity in cancer research.

The ACS-ASTRO Felix Feng, MD Clinician Scientist Development Award supports practicing radiation oncologists engaged in research that enhances health across the cancer continuum. Funded by the American Cancer Society and ASTRO, this award provides $730,000 over three to five years, aiming to advance the field of radiation oncology and improve patient care through innovative research and collaboration.

Incyte Corporation, a biopharmaceutical leader, offers healthcare sponsorships to support organizations focused on improving patient care and access to healthcare information. Eligible applicants include medical schools, associations, non-profits, advocacy groups, and hospitals. Requests should align with Incyte's commitment to enhancing the lives of patients affected by cancer and other diseases, ensuring compliance with regulatory guidelines. Organizations must enter a written agreement with Incyte to receive funding.

Incyte Corporation invites organizations to submit membership requests aimed at enhancing healthcare access for patients and advocates. As a biopharmaceutical leader, Incyte supports initiatives that align with its mission to improve patient lives through grants and contributions. Eligible entities include medical schools, associations, non-profits, and advocacy groups. Requests should comply with Incyte's regulatory standards and be submitted at least 60 days prior to the required decision date.

The 2026 Radiation Oncology Institute- Innovation Awards aim to advance cancer treatment by integrating radiation therapy with immunotherapy. Researchers are invited to submit proposals that explore optimal combinations of these modalities to enhance patient outcomes. Funding of up to $100,000 over two years will support projects focused on identifying effective treatment strategies, understanding mechanisms of synergy, and improving access to care. This initiative represents a significant opportunity for innovative research in oncology.

The Radiation Oncology Institute (ROI) Innovation Awards, offered by the American Society for Radiation Oncology, aim to accelerate innovative ideas in radiation therapy. Currently accepting applications for the 2026 awards, the program focuses on optimizing the combination of radiation therapy and immunotherapy to enhance cancer treatment outcomes. By supporting practical research, ROI strives to transform clinical practices and improve patient care in the fight against cancer.

Pfizer is offering a grant opportunity for independent medical education initiatives focused on Muscle Invasive Bladder Cancer (MIBC). This program aims to address the current knowledge gaps among healthcare professionals regarding emerging treatment data and its potential impact on clinical practices. By collaborating with Astellas, Pfizer seeks proposals that enhance awareness and understanding of the evolving MIBC landscape, ultimately improving patient outcomes in this critical area of unmet medical need.

The Joyce Bytof Memorial Cancer Survivors Scholarship, established by Joyce Bytof in collaboration with the American Cancer Society, supports childhood cancer survivors graduating from specific Wisconsin high schools. This scholarship aims to assist them in pursuing higher education despite the financial and academic challenges posed by their experiences. Joyce's legacy continues to inspire hope and resilience among young survivors as they strive for academic success and a brighter future.

The AACR-Torrey Coast Foundation Transpacific Gastric and Esophageal Cancer Research Partnership Grant supports innovative research on upper gastrointestinal malignancies, which are responsible for over one million deaths globally in 2023. This grant encourages collaboration between U.S. and Asian institutions, focusing on resistance, metastasis, and novel treatment strategies. Proposals should detail plans for clinical translation and are open to researchers at all career stages, especially those new to upper GI cancer research.

Bristol Myers Squibb Foundation Inc supports independent medical education to enhance healthcare professional competence and improve patient health outcomes. Their mission is to be a global leader in innovative medical education, focusing on evidence-based activities that address critical gaps in knowledge. By fostering excellence in healthcare, they aim to ensure measurable improvements in performance and patient outcomes across various disease areas.

The National Cancer Institute (NCI) invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity allows for biphasic or monophasic applications to support both analytical and clinical validation phases. Successful projects will leverage human specimens to develop assays that enhance cancer treatment and prevention, ensuring multidisciplinary collaboration among scientists and clinicians. This initiative aims to improve cancer management through reliable and clinically validated tools.

The American Heart Association is seeking proposals to study the prevalence and treatment of cardiovascular, kidney, and metabolic diseases among cancer patients and survivors. Given the over 16.7 million cancer survivors in the U.S., this research aims to highlight critical health disparities, identify treatment modalities, and explore shared risk factors. Applications focusing on underrepresented populations and utilizing real-world data sources are especially encouraged, aiming to improve health outcomes in this vulnerable group.

The ASCO Clinical Oncology & Research Experience (ASCO CORE) offers medical students immersive exposure to the field of oncology through shadowing experiences in clinical and research settings. With two distinct tracks, participants can gain insights into patient care or research practices, guided by mentors. Eligible students must be enrolled in a U.S. DO or MD program and maintain a good academic record. This program aims to inspire the next generation of oncology professionals.

Grants Program for Penn Investigators - Faculty Awards

Research grant applications in basic science, prevention, disease interception, and early detection that are relevant to the study of BRCA1/2 will be considered. The Basser Cancer Interception Institute focuses on funding new endeavors in emerging, orthogonal fields beyond DNA damage (e.g. mechanisms of haploinsufficiency, cancer evolution and tissue tropism). 

Grants focused on the following are of particular interest:

• Cancer interception and the pre-cancer disease state
• Issues relevant to men (including but not limited to prostate cancer, pancreatic cancer, male breast cancer)
• Potential for translation into clinical practice
• Early detection

Grants that demonstrate a potential for translation into clinical practice will be prioritized for funding.

Faculty Awards

Faculty awards are for two years with a funding level up to $200,000 per year.

Grants Program for Penn Investigators - Early career awards for Fellows, Postdocs and Instructors

Research grant applications in basic science, prevention, disease interception, and early detection that are relevant to the study of BRCA1/2 will be considered. The Basser Cancer Interception Institute focuses on funding new endeavors in emerging, orthogonal fields beyond DNA damage (e.g. mechanisms of haploinsufficiency, cancer evolution and tissue tropism). 

Grants focused on the following are of particular interest:

• Cancer interception and the pre-cancer disease state
• Issues relevant to men (including but not limited to prostate cancer, pancreatic cancer, male breast cancer)
• Potential for translation into clinical practice
• Early detection

Grants that demonstrate a potential for translation into clinical practice will be prioritized for funding.

Early career awards for Fellows, Postdocs and Instructors

Early career awards for Fellows, Postdocs and Instructors up to $100,000 for one year. Grants are eligible for competitive renewal upon reapplication and are contingent on progress the first year.

The National Cancer Institute (NCI) invites applications for the Toward Translation of Nanotechnology Cancer Interventions (TTNCI) program. This funding opportunity focuses on advanced pre-clinical research aimed at developing nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards will support the maturation of innovative nanomedicines using nanoparticles and nano-devices, enhancing cancer treatment efficacy. Successful projects will progress towards further NCI translational programs, such as the NExT initiative.